Summit Therapeutics' Ivonescimab Secures Third NMPA Approval in China for Lung Cancer Treatment
Event summary
- Ivonescimab, in combination with chemotherapy, received NMPA approval on August 12, 2026 for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC) in China.
- The approval is based on the HARMONi-6 Phase III trial, which demonstrated statistically significant and clinically meaningful superiority in both progression-free survival (PFS) and overall survival (OS).
- This marks the third NMPA-approved indication for an ivonescimab-containing regimen since its initial approval in May 2024.
- HARMONi-6 is the first Phase III study in NSCLC to show a statistically significant OS benefit over an anti-PD-(L)1 antibody plus chemotherapy regimen in a head-to-head setting.
The big picture
This approval solidifies ivonescimab as a potential next-generation immuno-oncology therapy, challenging the current standard of care for NSCLC. The success of HARMONi-6 sets a new benchmark in first-line cancer treatment, positioning Summit Therapeutics and Akeso Inc. at the forefront of innovative oncology solutions. The strategic partnership between Summit and Akeso continues to drive significant advancements in the field.
What we're watching
- Global Expansion
- How Summit Therapeutics will leverage this approval to accelerate the global development of ivonescimab in its licensed territories, including the United States and Europe.
- Clinical Pipeline
- The pace at which Summit can advance its ongoing Phase III clinical trials for ivonescimab in other cancer indications, such as colorectal cancer and urothelial carcinoma.
- Regulatory Strategy
- Whether the positive data from HARMONi-6 will strengthen Summit's case for future regulatory approvals in major markets outside China.
Related topics